COMP <GO>
EWTX vs JNJ // FREE CASH FLOW YIELD
Edgewise Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: EWTX 2
— JNJ 10
▲ FREE CASH FLOW YIELD LEADER: JNJ
LAST: $38.90 (-0.03%) • MKT CAP: $4.23B
fcf-yield
-3.41%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
fcf-yield
2.97%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EWTX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EWTX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -31.90% | 25.50% | -57.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -3.41% | 2.97% | -6.38 | JNJ | /fcf-yield <GO> |
| Operating Margin | -16.20% | 34.70% | -50.90 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 28.50% | -28.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -1.10% | 6.00% | -7.10 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | EWTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 8/9 | -5.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 60.4 | -14.65 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.08 | +0.02 | EWTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.0x | 23.0x | +2.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.23B | $662.49B | -$658.27B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EWTX REV | JNJ REV | EWTX GROSS % | JNJ GROSS % | EWTX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $94.19B | — | 67.9% | -$144.1M | $19.70B |
| FY 2024 | $0 | $88.82B | — | 69.1% | -$110.3M | $19.84B |
| FY 2023 | $0 | $85.16B | — | 44.0% | -$91.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EWTX // BETA 1.10
JNJ // BETA 1.08